Excitingly, blocking CCL2/CCR2 and CCL5/CCR5 signaling in vivo with the inhibitors RS102895, maraviroc and cenicriviroc significantly inhibited angiogenesis and vascular permeability in the lung PMN, especially cenicriviroc, which inhibited both CCR2 and CCR5 and was observed to have a powerful inhibitory effect on BC metastasis in this study, indicating a new strategy for the clinical prevention and treatment of BC metastasis. This evidence concerns the gene CCL5 and breast cancer.